Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: A randomized trial in malawi

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 338-344

  Nussbaum, Jesse C ^a,e   Jackson, Arthur ^a   Namarika, Dan ^a,b   Phulusa, Jacob ^a   Kenala, Jullita ^a   Kanyemba, Creto ^a   Jarvis, Joseph N ^c,d,g   Jaffar, Shabbar ^h   Hosseinipour, Mina C ^a,f   Kamwendo, Deborah ^a   Van Der Horst, Charles M ^f   Harrison, Thomas S ^g  

^a University of North Carolina Project   (Malawi)

^b KAMUZU CENTRAL HOSPITAL   (Malawi)

^c Institute of Infectious Disease and Molecular Medicine   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; FLUCYTOSINE; RIFAMPICIN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNGICIDAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER FUNCTION TEST; MALAWI; MALE; MENTAL HEALTH; MONOTHERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROPREVALENCE; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; CRYPTOCOCCUS; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; MALAWI; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749105005     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649861     Document Type: Article

References (32)

1. Gordon SB, Walsh AL, Chaponda M, et al. Bacterial meningitis in Malawian adults: pneumococcal disease is common, severe, and seasonal. Clin Infect Dis 2000;31:53-57. (Pubitemid 32268938)
2. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14:1401-1407.
3. 3. Scarborough M, Gordon SB, Whitty CJM, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441-2450. (Pubitemid 350272783)
4. 4. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg KA. Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis 2003; 36:652-662. (Pubitemid 36259573)
5. 5. Corbett EL, Churchyard GJ, Charalambos S, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002;34:1251-1258. (Pubitemid 34450674)
6. 6. French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-1038. (Pubitemid 34499426)
7. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009;23:525-530.
8. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998;26:1362-1366.
9. 9. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of'230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77:769-773. (Pubitemid 33116512)
10. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect. Dis 2006; 6:118.
11. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of HAART. Clin Infect Dis 2008;46:1694-1701.
12. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in south-western Uganda. Clin Infect Dis 2008;47:1556-1561.
13. van der Horst CM, Saag MS, Cloud GA, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997;337:15-21.
14. 14. Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28: 82-92. (Pubitemid 29246130)
15. Brouwer AE, Rajanuwong A, Chierakul W, et. al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-1767.
16. Bicanic T, Muzoora C, Brouwer A, et al. Independent association between rate of clearance of infection and outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009;49:702-709.
17. 17. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naïve or -experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45:76-80. (Pubitemid 46984619)
18. Larsen RA, Bozzette SA, Jones BE, et. al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994; 19:741-745.
19. 19. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS associated cryptococcal meningitis, Med Mycol 2008; 46:393-395. (Pubitemid 351552497)
20. Ministry of Health, Malawi. Management of HIV-related diseases. Lilongwe, Malawi: Ministry of Health, 2004:36-38.
21. Geel J, Pitt J, Orrell CJ, Van Dyk M, Wood R. Effect of fluconazole on nevirapine pharmacokinetics: International Conference on AIDS [abstract TuPeB4606], In: Program and abstracts of the 15th International Conference on AIDS (Bangkok). Geneva, Switzerland: International AIDS Society, 2004:369.
22. 22. Manosuthi W, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007; 7:14. (Pubitemid 46455921)
23. National AIDS Commission. (NAC) and Malawi Ministry of Health and Population. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. 2nd ed. Lilongwe, Malawi: Ministry of Health, April 2008. Available at http://www.hivunit.mohmw.org/Main/Antiretroviral Therapy. Accessed 20 May 2009.
24. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease: Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-718.
25. Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Tables for grading severity of adult and pediatric adverse events. Available at http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/Safety.htm. Accessed 20 May 2009.
26. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991;35:726-729
27. 27. Ding JC, Bauer M, Diamond DM, et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41:1589-1593 (Pubitemid 27289693)
28. 28. Diamond DM, Bauer M, Daniel BE, et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998;42:528-533 (Pubitemid 28114803)
29. 29. Kartalija M, Kaye K, Tureen JH, et al. Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologie and pathophysiologic outcome. J Infect Dis 1996;173:1216-1221 (Pubitemid 26251466)
30. 30. Brouwer AE, van Kan HJ, Johnson E, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51: 1038-1042 (Pubitemid 46355292)
31. 31. Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J. An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora. Chemotherapy 2003;49:17-23. (Pubitemid 36469790)
32. Muula AS, Chipeta J, Siziya S, Rudatsikira E, Mataya RH, Kataika E. Human resources requirements for highly active antiretroviral therapy scale-up in Malawi. BMC Health Serv Res 2007; 7:208. (Pubitemid 351207866)